{
    "body": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16757427", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22037271", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23090888", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22895079", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21279819", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23285088", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22985168", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17379100", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11808344", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19641300", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21672337", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14639002", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12755554", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20875546", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22160058", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16850123", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20425400", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22460758", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21672900", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11870241", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22461032", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12082821", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21892537", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12783369", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21903771", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23174189", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22087818", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22052279", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17382020", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22191306", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22506320", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23942795", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22349810", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19075651", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23666688", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16146726", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17956348", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20425355", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18974832", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15739279", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12869662", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17292736", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16988930", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12411298", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23032801", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21203982", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23233201", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12173333", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17970609", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20529808", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15899391", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15027317", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17364993", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21061842", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19064740", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12176881", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22519766", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12796373", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14744784", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18533795", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22151181", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17382013", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12750692", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17671641", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22761178", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16475128", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12200353", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15791812", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16689455", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18205699", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11986206", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22893108", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16843101", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19860186", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20607973", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19254884", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20945321", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12454739", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17929114"
    ], 
    "ideal_answer": [
        "The fusion protein BCR-ABL"
    ], 
    "exact_answer": [
        "BCR-ABL"
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010677", 
        "http://www.biosemantics.org/jochem#4275840", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011505", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016044", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015464", 
        "http://www.disease-ontology.org/api/metadata/DOID:8552"
    ], 
    "type": "factoid", 
    "id": "5324a8ac9b2d7acc7e000018", 
    "snippets": [
        {
            "offsetInBeginSection": 108, 
            "offsetInEndSection": 193, 
            "text": "CR-ABL-targeted TKI that inhibits BCR-ABL with greater potency compared with imatinib", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23942795", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 4, 
            "offsetInEndSection": 135, 
            "text": "reciprocal translocation between chromosomes 9 and 22 [t(9;22)(q34;q11), Philadelphia chromosome] creates a BCR-ABL1 fusion protein", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666688", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 655, 
            "offsetInEndSection": 780, 
            "text": "A novel tyrosine kinase inhibitor (TKI), imatinib, has been confirmed as an effective targeted treatment in most CML patients", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666688", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 184, 
            "text": "The availability of tyrosine kinase inhibitors (TKIs) has considerably changed the management of Philadelphia chromosome positive leukemia. The BCR-ABL inhibitor imatinib i", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23285088", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 270, 
            "offsetInEndSection": 492, 
            "text": "The BCR/ABL fusion tyrosine kinase is expressed in chronic myeloid leukemia and Philadelphia-positive (Ph+) acute lymphoblastic leukemia cells, and its inhibition by the clinically used tyrosine kinase inhibitors imatinib ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23233201", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 183, 
            "text": "Chronic myeloid leukemia (CML) is a clonal malignant myeloproliferative disorder characterized by the expansion of hematopoietic cells carrying the Philadelphia chromosome", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23174189", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 437, 
            "offsetInEndSection": 556, 
            "text": "Patients received imatinib after diagnosis and underwent regular laboratory monitoring (quantification of BCR-ABL ratio", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23174189", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 217, 
            "offsetInEndSection": 494, 
            "text": "CML is characterized by a balanced genetic translocation, t(9;22)(q34;q11.2), involving a fusion of the Abelson oncogene (ABL) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090888", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 668, 
            "offsetInEndSection": 711, 
            "text": "tyrosine kinase inhibitors (TKIs), imatinib", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090888", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 143, 
            "offsetInEndSection": 346, 
            "text": "Characterized by a translocation between chromosomes 9 and 22, known as the Philadelphia chromosome, small-molecule tyrosine kinase inhibitors (TKIs) targeted against the oncogenic BCR-ABL fusion protein", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23032801", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 176, 
            "text": "Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22985168", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 361, 
            "offsetInEndSection": 398, 
            "text": "ABL-kinase inhibitors (AKIs) Imatinib", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22985168", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1, 
            "offsetInEndSection": 120, 
            "text": "hiladelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is triggered by constitutively activated BCR-ABL", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22895079", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 280, 
            "offsetInEndSection": 324, 
            "text": " BCR-ABL tyrosine kinase inhibitor imatinib ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22895079", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1, 
            "offsetInEndSection": 56, 
            "text": "matinib was the first BCR-ABL tyrosine kinase inhibitor", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22893108", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 26, 
            "offsetInEndSection": 185, 
            "text": "CML) is a pluripotent hematopoietic disorder that is currently considered incurable. The tyrosine kinase product of the Philadelphia chromosome, P210 BCR-ABL, ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22761178", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 322, 
            "offsetInEndSection": 385, 
            "text": "Imatinib mesylate, an orally available BCR-ABL kinase inhibitor", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22761178", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 14, 
            "offsetInEndSection": 193, 
            "text": "Since the initial approval of imatinib much has been learned about its resistance mechanisms, and efforts have continued to improve upon BCR-ABL tyrosine kinase inhibitor therapy.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22519766", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 26, 
            "offsetInEndSection": 202, 
            "text": "CML) originates from a hematopoietic stem cell carrying the Philadelphia (Ph) chromosome and oncogenic BCR-ABL1 fusion gene. The first tyrosine-kinase inhibitor (TKI) imatinib ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22506320", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 131, 
            "offsetInEndSection": 171, 
            "text": "chronic myeloid leukemia (CML) patients ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22461032", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 363, 
            "offsetInEndSection": 455, 
            "text": "Philadelphia chromosome and/or BCR-ABL positive, received first-line treatment with imatinib", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22461032", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1, 
            "offsetInEndSection": 152, 
            "text": "matinib mesylate is the sole BCR-ABL tyrosine kinase inhibitor approved as first-line treatment of accelerated-phase (AP) chronic myeloid leukemia (CML", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22460758", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 9, 
            "offsetInEndSection": 64, 
            "text": "Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22349810", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 16, 
            "offsetInEndSection": 160, 
            "text": "Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has revolutionized the treatment of Bcr-Abl positive chronic myeloid leukemia ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22191306", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 309, 
            "offsetInEndSection": 575, 
            "text": "The development of first-generation (imatinib) and second-generation (dasatinib and nilotinib) tyrosine kinase inhibitors (TKIs) that target the BCR-ABL1 fusion protein produced by the Ph chromosome revolutionized the treatment of chronic myelogenous leukemia (CML).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22160058", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 219, 
            "text": "The cytogenetic characteristic of Chronic Myeloid Leukemia (CML) is the formation of the Philadelphia chromosome gene product, BCR-ABL. Given that BCR-ABL is the specific target of Gleevec in CML treatment, ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22151181", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 3, 
            "offsetInEndSection": 137, 
            "text": "chronic myeloid leukemia (CML), BCR-ABL-mediated oncogenic signaling can be successfully targeted with the BCRABL- inhibitors imatinib", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22087818", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1, 
            "offsetInEndSection": 195, 
            "text": "matinib mesylate (STI 571; Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) is an orally available tyrosine kinase inhibitor that targets a constitutively activated BCR-ABL tyrosine kinase", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22052279", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 380, 
            "offsetInEndSection": 448, 
            "text": "Philadelphia chromosome positive chronic myelogenous leukemia (CML) ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22052279", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 26, 
            "offsetInEndSection": 263, 
            "text": "CML) is caused by the BCR-ABL oncogene. The Philadelphia chromosome (Ph) from a reciprocal translocation, t(9;22) (q34;q11) causes a fusion gene, BCR-ABL, that encodes a constitutively active tyrosine kinase. Treatment of CML by imatinib", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22037271", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 343, 
            "offsetInEndSection": 357, 
            "text": "BCR-ABL levels", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21903771", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 9, 
            "offsetInEndSection": 125, 
            "text": "Imatinib induces a durable response in most patients with Philadelphia chromosome-positive chronic myeloid leukemia,", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21903771", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 167, 
            "offsetInEndSection": 295, 
            "text": "CML is a myeloproliferative disorder characterized by the presence of the Philadelphia chromosome or the BCR-ABL fusion oncogene", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21892537", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 357, 
            "offsetInEndSection": 373, 
            "text": "imatinib therapy", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21892537", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 971, 
            "offsetInEndSection": 1186, 
            "text": "The discovery of targeted tyrosine kinase inhibition of BCR-ABL kinase dramatically changed the treatment of CML. Imatinib, the first TKI approved for treatment of patients with Philadelphia chromosome--positive CML", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21672900", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 27, 
            "offsetInEndSection": 299, 
            "text": "CML) is a genetically associated malignancy of haematopoietic stem cells, characterized by a t(9;22) translocation that forms the Philadelphia chromosome and creates a novel fusion gene, BCR-ABL. Treatment with molecular-targeted therapy is usually initiated with imatinib", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21672337", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 492, 
            "offsetInEndSection": 603, 
            "text": "imatinib, a selective BCR-ABL tyrosine kinase inhibitor (TKI), was started but Ph-positive chromosomes remained", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21279819", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 651, 
            "offsetInEndSection": 848, 
            "text": "CML is induced by the BCR-ABL oncogene, whose gene product is a BCR-ABL tyrosine kinase. Currently, inhibition of BCR-ABL kinase activity by its kinase inhibitor such as imatinib mesylate (Gleevec)", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21203982", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 414, 
            "offsetInEndSection": 518, 
            "text": "The Bcr-Abl tyrosine kinase inhibitor imatinib represented a major advance over conventional CML therapy", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17382013", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 231, 
            "offsetInEndSection": 352, 
            "text": "Imatinib (Glivec, Gleevec), a specific small molecule inhibitor of Bcr-Abl, has become the standard drug therapy for CML,", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17379100", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 336, 
            "offsetInEndSection": 416, 
            "text": "Imatinib blocks proliferation and induces apoptosis of BCR-ABL-expression in CML", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17364993", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 191, 
            "offsetInEndSection": 429, 
            "text": "CML is the presence of a balanced translocation between the long arms of chromosomes 9 and 22, t(9;22)(q34;q11.2), which is known as the Philadelphia (Ph) chromosome. This translocation results in the formation of the bcr-abl fusion gene,", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17292736", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 984, 
            "offsetInEndSection": 1005, 
            "text": "emergence of imatinib", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17292736", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1, 
            "offsetInEndSection": 210, 
            "text": "matinib mesylate, binding to the inactive conformation of Bcr-Abl tyrosine kinase and suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic myeloid leukaemia (CML) patients.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16988930", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 14, 
            "offsetInEndSection": 312, 
            "text": "Ph) chromosome is the cytogenetic hallmark of chronic myeloid leukemia (CML). The translocation forms a chimeric gene, bcr-abl, which generates BCR-ABL. This fusion protein constitutively activate ABL tyrosine kinase and causes CML. Imatinib mesylate is a selective tyrosine kinase inhibitor on ABL", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16850123", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 26, 
            "offsetInEndSection": 244, 
            "text": "CML) is characterized by the presence of a BCR-ABL fusion gene, which is the result of a reciprocal translocation between chromosomes 9 and 22, and is cytogenetically visible as a shortened chromosome 22 (Philadelphia)", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16843101", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 528, 
            "offsetInEndSection": 595, 
            "text": "imatinib mesylate was introduced into the treatment regimen for CML", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16843101", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1, 
            "offsetInEndSection": 179, 
            "text": "matinib was developed as the first molecularly targeted therapy to specifically inhibit the BCR-ABL kinase in Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML)", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16757427", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1, 
            "offsetInEndSection": 218, 
            "text": "hronic myelogenous leukemia is characterized by the Philadelphia-chromosome, a shortened chromosome 22 which is the result of a reciprocal translocation between chromosome 9 and 22. The fusion gene is called BCR-ABL. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16689455", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 594, 
            "offsetInEndSection": 621, 
            "text": "Imatinib mesylate (Glivec) ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16689455", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 487, 
            "offsetInEndSection": 611, 
            "text": " BCR-ABL transcripts in the peripheral blood of patients with CML who were treated with imatinib mesylate (Glivec, Novartis)", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16475128", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 367, 
            "offsetInEndSection": 450, 
            "text": "Imatinib was the first small molecule developed to inhibit BCR-ABL tyrosine kinase ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16146726", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1, 
            "offsetInEndSection": 60, 
            "text": "hronic myeloid leukemia cells contain a BCR-ABL oncoprotein", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16146726", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 16, 
            "offsetInEndSection": 246, 
            "text": "Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against the breakpoint cluster region--Abelson murine leukemia (BCR-ABL) tyrosine kinase has been developed for treatment of chronic myelogenous leukemia (CML).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21061842", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 93, 
            "offsetInEndSection": 489, 
            "text": "The hallmark of CML is an acquired chromosomal translocation known as the Philadelphia chromosome (Ph), which results in the synthesis of the breakpoint cluster region-Abelson murine leukemia (BCR-ABL) fusion oncoprotein, a constitutively active tyrosine kinase. The introduction of imatinib, a tyrosine kinase inhibitor (TKI) that is specific for BCR-ABL, was a major breakthrough in CML therapy", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20945321", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1135, 
            "offsetInEndSection": 1157, 
            "text": "original TKI, imatinib", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20875546", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 518, 
            "offsetInEndSection": 759, 
            "text": "CML were the discovery of the Philadelphia chromosome in 1960, and of the (9;22) translocation in 1973. There followed definition of the breakpoint cluster region on chromosome 22 in 1984 and the demonstration of the BCR-ABL transcript in CM", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20875546", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 14, 
            "offsetInEndSection": 186, 
            "text": "Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has proved to be most effective therapy of Philadelphia chromosome-positive chronic myelogenous leukemia. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20607973", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 93, 
            "offsetInEndSection": 415, 
            "text": "The hallmark of CML is an acquired chromosomal translocation known as the Philadelphia chromosome (Ph) that results in the synthesis of the BCR-ABL fusion protein, a constitutively active tyrosine kinase (TK). The introduction of imatinib, a TK inhibitor (TKI) specific for BCR-ABL, was a major breakthrough in CML therapy", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20529808", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 338, 
            "offsetInEndSection": 439, 
            "text": "CML has enabled the development of Abl-specific tyrosine kinase inhibitors, such as imatinib mesylate", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20425400", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 26, 
            "offsetInEndSection": 150, 
            "text": "CML) arises as a consequence of a chromosomal translocation giving rise to the Philadelphia chromosome and Bcr-Abl oncogene.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20425400", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 26, 
            "offsetInEndSection": 133, 
            "text": "CML) is a paradigm for neoplasias that are defined by a unique genetic aberration, the BCR-ABL1 fusion gene", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19860186", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 213, 
            "offsetInEndSection": 257, 
            "text": "protein tyrosine kinase inhibitor, imatinib,", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19860186", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 4, 
            "offsetInEndSection": 150, 
            "text": "BCR-ABL fusion gene represents the hallmark of chronic myelogenous leukemia (CML) and is derived from a translocation between chromosome 9 and 22.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19641300", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 370, 
            "offsetInEndSection": 406, 
            "text": "CML patients with imatinib treatment", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19641300", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 26, 
            "offsetInEndSection": 244, 
            "text": "CML) is characterized by the presence of the Philadelphia chromosome (Ph), a genetic aberration that codes for bcrabl, which plays a key role in disease pathophysiology. The first oral inhibitor of Brc-Abl was imatinib", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19254884", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 26, 
            "offsetInEndSection": 328, 
            "text": "CML) is characterized by the presence of the Philadelphia (Ph) chromosome, which results from a reciprocal translocation between the long arms of the chromosomes 9 and 22 t(9;22)(q34;q11). This translocation creates two new genes, BCR-ABL on the 22q- (Ph chromosome) and the reciprocal ABL-BCR on 9q-. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19075651", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 704, 
            "offsetInEndSection": 801, 
            "text": "tyrosine kinase inhibitor (TKI), introduced into clinical practice in 1998, was imatinib mesylate", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19075651", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 465, 
            "offsetInEndSection": 613, 
            "text": "BCR-ABL tyrosine kinase is the critical pathogenetic event in CML and an ideal target for therapy. This was confirmed in clinical trials of imatinib", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19064740", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 26, 
            "offsetInEndSection": 290, 
            "text": "CML) is characterized by the presence of a constitutively active Abl kinase, which is the product of a chimeric BCR-ABL gene, caused by the genetic translocation known as the Philadelphia chromosome. Imatinib, a selective inhibitor of the Bcr-Abl tyrosine kinase, ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18974832", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 26, 
            "offsetInEndSection": 279, 
            "text": "CML) is the first human malignancy for which the promise of targeted therapy has come true. CML is invariably associated with a specific genetic lesion--the t(9;22) chromosomal translocation. As a consequence of this translocation, a BCR-ABL fusion gene", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18533795", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 545, 
            "offsetInEndSection": 631, 
            "text": "Imatinib mesylate, an orally available tyrosine kinase inhibitor that targets Bcr-Abl,", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18533795", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1, 
            "offsetInEndSection": 173, 
            "text": "CR-ABL tyrosine kinase inhibitors, such as imatinib (Gleevec) are highly effective in treating human Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18205699", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 174, 
            "text": "Chronic myeloid leukemia (CML) is a hematopoietic stem cell cancer driven by the BCR-ABL fusion protein that arises from the translocation of chromosomes 9 and 22", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17970609", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 969, 
            "offsetInEndSection": 1005, 
            "text": "BCR-ABL inhibitors, such as imatinib", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17970609", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 509, 
            "offsetInEndSection": 577, 
            "text": "TKIs (tyrosine kinase inhibitors), including IM (imatinib mesylate),", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17956348", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 5, 
            "offsetInEndSection": 228, 
            "text": "chronic myeloid leukaemia) is a myeloproliferative disease that originates in an HSC (haemopoietic stem cell) as a result of the t(9;22) translocation, giving rise to the Ph (Philadelphia chromosome) and bcr-abl oncoprotein", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17956348", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 26, 
            "offsetInEndSection": 310, 
            "text": "CML) was the first human malignant disease to be linked to a single, acquired genetic abnormality. Identification of the Bcr-Abl kinase fusion protein and its pivotal role in the pathogenesis of CML provided new opportunities to develop molecular-targeted therapies. Imatinib mesylate", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17929114", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 3, 
            "offsetInEndSection": 297, 
            "text": " identification of the Philadelphia chromosome in cells from individuals with chronic myelogenous leukemia (CML) led to the recognition that the BCR-ABL tyrosine kinase causes CML. This in turn led to the development of imatinib mesylate, a clinically successful inhibitor of the BCR-ABL kinase", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17671641", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 26, 
            "offsetInEndSection": 441, 
            "text": "CML) was the first human malignancy to be associated with a single genetic abnormality, characterized by a reciprocal translocation involving chromosomes 9 and 22 (the Philadelphia chromosome). The fusion gene that results (BCR-ABL) produces a constitutively activated tyrosine kinase that exists in different isoforms depending on BCR break-points. Imatinib mesylate is a highly selective inhibitor of this kinase,", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20425355", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 26, 
            "offsetInEndSection": 358, 
            "text": "CML) is characterized by the presence of the Philadelphia chromosome, which is associated with a balanced translocation involving chromosomes 9 and 22 to produce a fusion gene (bcr-abl) that gives rise to a constitutively activated Abl tyrosine kinase. This kinase led to the discovery of several small-molecule inhibitors, imatinib", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17382020", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1, 
            "offsetInEndSection": 163, 
            "text": "matinib mesylate was designed as an inhibitor targeting the BCR-ABL tyrosine kinase, the molecular counterpart of the Philadelphia translocation t(9;22)(q34;q11).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15899391", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 30, 
            "offsetInEndSection": 431, 
            "text": "CML) is a clonal hematopoietic disorder caused by the reciprocal translocation between chromosome 9 and 22. As a result of this translocation, a novel fusion gene, BCR-ABL, is created on Philadelphia (Ph) chromosome, and the constitutive activity of the BCR-ABL protein tyrosine kinase plays a critical role in the disease pathogenesis. Imatinib mesylate, a selective BCR-ABL tyrosine kinase inhibitor", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15791812", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 187, 
            "offsetInEndSection": 458, 
            "text": "CML was the first human cancer demonstrated to be strongly associated to the presence of a recurrent chromosomal translocation (the t(9;22)(q34;q11) that creates the Philadelphia (Ph)-chromosome) and to a specific molecular defect, the formation of a hybrid BCR-ABL gene ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15739279", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 651, 
            "offsetInEndSection": 747, 
            "text": "imatinib, (Glivec, Gleevec, Novartis), a potent tyrosine kinase inhibitor of the Bcr-Abl protein", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15739279", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1, 
            "offsetInEndSection": 391, 
            "text": "matinib mesylate is a new drug that can inhibit the tyrosine kinase activity of Bcr-Abl, the receptors for platelet-derived growth factor receptor(PDGF) and stem cell factor, or c-kit. Chronic myeloid leukemia (CML) is distinguished by the presence of a reciprocal translocation between chromosomes 9 and 22 that results in a shortened chromosome 22, termed the Philadelphia(Ph) chromosome.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15027317", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 19, 
            "offsetInEndSection": 51, 
            "text": "IM) binds to the BCR-ABL protein", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/14744784", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 4, 
            "offsetInEndSection": 224, 
            "text": "Philadelphia chromosome found in leukemia cells of chronic myelogenous leukemia (CML) patients is produced by translocation between chromosomes 9 and 22, resulting in expression of a chimera protein of Bcr and Abl kinase", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/14639002", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 351, 
            "offsetInEndSection": 416, 
            "text": "Abl kinase inhibitors were synthesized. STI571 (imatinib mesylate", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/14639002", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 26, 
            "offsetInEndSection": 167, 
            "text": "CML) is characterized by the Philadelphia translocation that fuses BCR sequences from chromosome 22 upstream of the ABL gene on chromosome 9.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12869662", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 321, 
            "offsetInEndSection": 380, 
            "text": "Imatinib, an ATP-competitive selective inhibitor of Bcr-Abl", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12869662", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 9, 
            "offsetInEndSection": 183, 
            "text": "Imatinib mesylate is a tyrosine kinase inhibitor with high affinity for the BCR-ABL fusion protein expressed by the hematopoietic cells in chronic myelogenous leukemia (CML).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12796373", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 319, 
            "offsetInEndSection": 414, 
            "text": "BCR/ABL, encodes an activated tyrosine kinase that can act alone to induce a CML-like syndrome ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12783369", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 545, 
            "offsetInEndSection": 593, 
            "text": "The kinase inhibitor imatinib mesylate (Gleevec)", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12783369", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 5, 
            "offsetInEndSection": 240, 
            "text": "hiladelphia chromosome translocation (t(9;22)) results in the molecular juxtaposition of two genes, BCR and ABL, to form an aberrant BCR-ABL gene on chromosome 22. BCR-ABL is critical to the pathogenesis of chronic myelogenous leukemia", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12755554", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 634, 
            "offsetInEndSection": 661, 
            "text": "imatinib mesylate (Gleevec,", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12755554", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1, 
            "offsetInEndSection": 180, 
            "text": "matinib mesylate (Glivec) is a selective inhibitor of bcr-abl tyrosine kinase, the product of the Philadelphia chromosome, which is the hallmark of chronic myeloid leukaemia (CML)", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12750692", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1, 
            "offsetInEndSection": 174, 
            "text": "matinib mesylate (STI571, Glivec, Gleevec) is a powerful inhibitor of the tyrosine kinase activity of Bcr-Abl, the oncoprotein responsible for chronic myeloid leukemia (CML)", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12454739", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 30, 
            "offsetInEndSection": 238, 
            "text": "CML) is characterized by the presence of a Bcr-Abl fusion protein with deregulated tyrosine kinase activity that is required for maintaining the malignant phenotype. Imatinib, a selective inhibitor of Bcr-Abl", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12411298", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 314, 
            "offsetInEndSection": 398, 
            "text": "Imatinib is an orally administered, potent inhibitor of the Bcr-Abl tyrosine kinase.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200353", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 211, 
            "offsetInEndSection": 328, 
            "text": "Imatinib mesylate (STI571), a selective inhibitor of the Bcr-Abl tyrosine kinase, has significant activity in AP CML.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12176881", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 320, 
            "text": "Chronic myelogenous leukemia (CML) is characterized by a molecular aberration, a fusion BCR-ABL gene encoding for aberrant tyrosine kinase activity, which is crucial in the pathogenesis of CML. In vitro, inhibition of BCR-ABL protein tyrosine kinase activity by a tyrosine kinase inhibitor, Imatinib mesylate", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12173333", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 27, 
            "offsetInEndSection": 497, 
            "text": "CML) is characterised by the occurrence of the Philadelphia (Ph) chromosome (9/22 translocation) and the formation of a fusion protein--the BCR-ABL transcript with constitutive activation of the BCR-ABL tyrosine kinase and consequent changes in the intracellular signal transduction, which is responsible for the deregulated myeloid cell proliferation. STI571 (signal transduction inhibition number 571) is a potent and selective inhibitor of the BCR-ABL tyrosine kinase", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12082821", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 199, 
            "offsetInEndSection": 356, 
            "text": "Imatinib mesylate (STI571), a specific Bcr-Abl tyrosine-kinase signal-transduction inhibitor, has shown encouraging activity in phase I and II studies of CML", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/11986206", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 209, 
            "text": "Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/11870241", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 26, 
            "offsetInEndSection": 265, 
            "text": "CML) is a clonal hematopoietic stem cell disorder characterized by Philadelphia chromosome and resultant production of the constitutively activated BCR-ABL tyrosine kinase. Imatinib (STI571), selective inhibitor of the ABL-tyrosine kinase,", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/11808344", 
            "endSection": "abstract"
        }
    ]
}